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Background: Although a number of risk assessment models are available for estimating 10-
year risk of cardiovascular (CV) events in patients requiring primary prevention of CV
disease, the predictive accuracy of the contemporary risk models has not been adequately
evaluated in Indians.
Methods: 149 patients [mean age 59.4 ± 10.6 years; 123 (82.6%) males] without prior CV
disease and presenting with acute myocardial infarction (MI) were included. The four
clinically most relevant risk assessment models [Framingham Risk score (RiskFRS), World
Health Organization risk prediction charts (RiskWHO), American College of Cardiology/
American Heart Association pooled cohort equations (RiskACC/AHA) and the 3rd Joint
British Societies' risk calculator (RiskJBS)] were applied to estimate what would have been
their predicted 10-year risk of CV events if they had presented just prior to suffering the
acute MI.
Results: RiskWHO provided the lowest risk estimates with 86.6% patients estimated to be
having <20% 10-year risk. In comparison, RiskFRS and RiskACC/AHA returned higher risk
estimates (61.7% and 69.8% with risk <20%, respectively; p values <0.001 for comparison
with RiskWHO). However, the RiskJBS identified the highest proportion of the patients as
being at high-risk (only 44.1% at <20% risk, p values 0 < 0.01 for comparison with all the
other 3 risk scores).
Conclusions: This is the first study to show that in Indian patients presenting with acute MI,
RiskJBS is likely to identify the largest proportion of the patients as at ‘high-risk’ as
compared to RiskWHO, RiskFRS and RiskACC/AHA. However, large-scale prospective studies are
needed to confirm these findings.
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Estimation of the risk of future cardiovascular (CV) events is
an essential first step in themanagement of patients requiring
primary prevention of CV disease (CVD). Such an estimate not
only provides prognostically relevant information but more
importantly, also provides the framework for selecting the
nature and the intensity of the appropriate preventive
therapies.
Traditionally, assessment of the CV risk is performed by
determining the presence and severity of the major CV risk
factors and subsequently using risk algorithms and prediction
charts to determine the overall CV risk in any given individual.
A number of risk assessment tools are available for this pur-
pose such as Framingham risk score (RiskFRS),
1,2 Prospective
Cardiovascular Munster Score (PROCAM),3 Systemic Coronary
Risk Evaluation (SCORE),4 QRISK,5e7 and the more recently
developedWorld Health Organization/International Society of
Hypertension CVD risk prediction charts (RiskWHO),
8 American
College of Cardiology/American Heart Association (ACC/AHA)
pooled cohort equations (RiskACC/AHA)
9 and the 3rd Joint
British Societies' risk calculator (RiskJBS).
10
A major prerequisite for the appropriate use of these risk
predictionmodels is their contemporariness and their validity
in the particular ethnic group. Unfortunately, none of the
currently available risk predictionmodels is based on the data
derived from resident Indians who have consistently been
shown to have significantly higher risk of CVD than the
western populations.11e17 Because of the lack of a specific risk
scoring system available for Indians, the physicians in India
are left with little choice but to adopt the same risk scores as
applicable to the western populations. In this context, it be-
comes important to determine which one of the currently
available risk assessment models comes closest to estimating
the actual risk in Indian subjects.With the recent introduction
of newer risk scores, namely RiskWHO, RiskACC/AHA and RiskJBS,
this question becomes even more pertinent than ever.
Therefore, in the present study we sought to determine the
accuracy of 4 clinically most relevant risk assessment models
(RiskFRS, RiskWHO, RiskACC/AHA and RiskJBS) in Indian patients
presentingwith first acutemyocardial infarction (MI). Our goal
was to determine how accurately these different risk scores
would have identified these patients to be at ‘high-risk’ had
they presented just prior to suffering the acute MI.2. Methods
The study included 149 subjects without any prior history of
CVD who had presented with acute MI. The diagnosis of MI
was based on the third universal definition of MI.18 As per this
definition, a diagnosis of MI required a rise and/or fall of car-
diac biomarker values (preferably cardiac troponin) with at
least one value above the 99th percentile upper reference
limit, along with either the symptoms of ischemia and/or new
or presumed new significant ST-T changes or new left bundle
branch block. The MI was labeled as ST-segment elevation MI
(STEMI) if the ECG revealed new ST elevation at the J point in
two contiguous leads (0.1 mV in all leads other than leadsV2eV3 and in case of leads V2eV3 0.2 mV in men 40 years,
0.25 mV in men <40 years or 0.15 mV in women) or new
onset left bundle branch block. If none of these ECG changes
were present, then it was labeled as non-STEMI.
All patients were admitted to the cardiac intensive care
unit and were managed according to the existing recom-
mendations for the management of patients presenting with
acute MI.19,20 Clinical evaluation was performed as part of
their management and included detailed history and physical
examination. History was obtained regarding prior cardiac
illness, presence or absence of major CV risk factors, and the
presenting symptoms. The physical examination included
recording of vital parameters, cardiovascular examination
and other systemic examination. The height and weight were
also recorded, either at the time of presentation or within first
24 h in patients who could be ambulated.
In all patients, routine biochemical investigations were
performed including complete blood count, renal function
tests, cardiac enzymes, fasting and random blood glucose,
hemoglobin A1C and fasting lipid profile. Fasting lipid profile
was performed on the first morning after the initial
presentation.
2.1. Estimation of CV risk
Based on the information collected, 10-year risk of having a
major CV event (CV death, MI or stroke) was calculated for
each patient using the four different risk scores- RiskFRS,
RiskJBS, RiskACC/AHA, and RiskWHO. The RiskFRS and the Ris-





ectively. The RiskJBS is available as an online calculator (or as
a downloadable Smartphone app) from www.jbs3risk.com.
The WHO risk prediction charts are included as part of the
‘Guideline for assessment and management of cardiovascu-
lar risk’ available at the WHO website (http://www.who.int/
cardiovascular_diseases/publications/Prevention_of_
Cardiovascular_Disease/en/). The chart applicable for South-
East Asian region D (which includes Bangladesh, Bhutan,
Democratic People's Republic of Korea, India, Maldives,
Myanmar and Nepal) was used in the present study.
The parameters included in each of these risk scores and
the applicable ranges are presented in Table 1. As the RiskACC/
AHA accepts 130 mg/dl as the minimum value of total choles-
terol (TC), the same was used for estimating CV risk in in-
dividualswho had TC<130mg/dl (n¼ 37, 24.8%). Similarly, in 2
patients (1.3%) higher values of age (35 years) and in 32 pa-
tients (21.5%) higher values of systolic blood pressure (SBP,
110 mmHg) were used for estimating CV risk according to
RiskWHO because the actual valueswere below the lower limits
acceptable for the WHO risk prediction charts. No other ad-
justments were required in the input variables for estimation
of CV risk by any of the studied risk scores.
It is noteworthy that unlike all other risk scoring methods,
RiskWHO uses approximates ranges of input variables and
provides 10-year risk estimates as risk categories rather than
absolute values. Therefore, to allow comparison, the
Table 1 e Clinical and biochemical parameters (along with applicable ranges) included in various cardiovascular risk
assessment models.
Variable FRS JBS risk score ACC/AHA risk score WHO risk prediction charts
Age Yes (30e74 years) Yes (30e84 years) Yes (20e79 years) Yes (z35e75 years)
Gender Yes Yes Yes Yes
Ethnicity X Yes Yes X
History of diabetes Yes Yes Yes Yes
Smoking history Yes Yes Yes Yes
Family history of premature CVD X Yes X X
History of atrial fibrillation X Yes X X
History of chronic kidney disease X Yes X X
History of rheumatoid arthritis X Yes X X
History of blood pressure treatment Yes Yes Yes X
Systolic blood pressure Yes (90e200 mmHg) Yes (70e210 mmHg) Yes (90e200 mmHg) Yes (z110e190 mmHg)
Body-mass index X Yes (20e50 kg/m2) X X
Total cholesterol Yes (100e405 mg/dl) Yesa Yes (130e320 mg/dl) Yes (z3.5e8.5 mmol/L)
HDL-cholesterol Yes (10e100 mg/dl) Yesa Yes (20e100 mg/dl) X
ACC, American College of Cardiology; AHA, American Heart Association; CVD, cardiovascular disease; FRS, Framingham risk score; HDL, high-
density lipoprotein; JBS, Joint British Society; WHO, World Health Organization.
a The risk calculator accepts all usually found values of total and HDL-cholesterol but when total cholesterol exceeds 7.5 mmol/L, it highlights
the possibility of familial hypercholesterolemia.
Table 2 e Clinical and biochemical characteristics of the
study population.
Parameter Valuesa (n ¼ 149)
Age (years) 59.4 ± 10.6
Male gender, n (%) 123 (82.6)
Hypertension, n (%) 86 (57.7)
Diabetes mellitus, n (%) 69 (46.3)
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 5 8 0e5 8 6582estimated 10-year risks by all the different risk assessment
models were divided in to the following risk categories- <10%,
10e19.9%, 20e29.9%, 30e39.9% and 40%. However, in case of
RiskFRS, the two highest risk categories were combined as this
risk score does not provide absolute risk value once the esti-
mated 10-year risk exceeds 30%. In addition, for the purpose of
analysis, the estimated 10-year risks were also categorized as
<20% and 20%, the traditional cut-off values used to define
high CV risk.Current smokers, n (%) 41 (27.5)
Family history of premature CVD, n (%) 35 (23.5)
Body-mass index (kg/m2) 24.9 ± 4.3
Heart rate (beats/min) 89 ± 17
Systolic blood pressure (mmHg) 117.2 ± 20.7
Diastolic blood pressure (mmHg) 69.7 ± 13.7
Type of myocardial infarction
STEMI 123 (82.6)
Non-STEMI 26 (17.4)
Location of myocardial infarction (STEMI only)




Antiplatelet agents 139 (93.3)
Anticoagulants 88 (59.1)
Statins 141 (94.6)
ACEI or ARB 63 (42.3)
Beta-blockers 72 (48.3)
Percutaneous or surgical coronary 129 (86.6)3. Statsitical analysis
The data were managed on Microsoft excel spreadsheet
(version 2007, Microsoft Corp, Seattle, Washington) and
analyzed using SPSS for Windows (release 15.0, SPSS Inc,
Chicago, IL, USA). All values were expressed as mean (±stan-
dard deviation) or as percentages. Standard descriptive anal-
ysis was performed to analyze the baseline characteristics of
the study population. The categorized risk estimates derived
from the different risk scores were compared either using
Wilcoxon's signed rank test (for multiple risk categories) or
using McNemar test (when the risk scores were dichotomized
as <20% or 20%). Pearsons' correlation coefficient (r)
was estimated to assess the relationship between RiskJBS and
RiskACC/AHA. A p value <0.05 was considered statistically
significant.revascularization
Fasting blood glucose (mg/dL) 140.9 ± 44.7
Total cholesterol (mg/dL) 145.2 ± 44.0
Serum triglycerides (mg/dL) 139.3 ± 79.5
HDL-cholesterol (mg/dL) 35.1 ± 11.3
LDL-cholesterol (mg/dL) 88.6 ± 35.9
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; CVD, cardiovascular disease; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; STEMI, ST segment
elevation myocardial infarction.
a All values are mean ± standard deviation or actual number with
percentages in parentheses.4. Results
The baseline characteristics of the study population are pre-
sented in Table 2. The mean age of the study subjects was
59.4 ± 10.6 years and 123 (82.6%) were males. The conven-
tional, major CV risk factors were common in the study sub-
jects with nearly half having hypertension or diabetes (57.7%
and 46.3% respectively), 27.5% being current smokers and
23.5% having family history of premature CVD.
Fig. 1 e The estimated 10-year cardiovascular risk
according to the four risk assessment models. *The two
highest risk categories were combined for RiskFRS which
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 5 8 0e5 8 6 5834.1. Clinical and treatment details pertaining to MI
(Table 2)
Of the 149 patients, 123 (82.6%) had presented with STEMI and
the remaining had presented with non-STEMI. Among those
with STEMI, nearly two-thirds (65.0%) had anterior wall MI
and the remaining 35% had MI involving other regions. The
median time interval from the onset of symptoms to the
presentation at our center was 2.0 h (interquartile range
1.5e4.5 h). The heart rate at presentation was 89 ± 17 beats/
min and the SBP and diastolic BP were 117.2 ± 20.7 mmHg
and 69.7 ± 13.7 mmHg, respectively. The creatine phosphoki-
nase MB fraction was 74.7 ± 104.9 u/L and troponin I was
28.3 ± 66.7 ng/mL. Of the 123 patients with STEMI, 37 (30.1%)
received thrombolysis. Overall, 129 (86.6%) patients under-
went revascularization (92 percutaneous, 35 surgical and 2
both) during the hospital stay. Antiplatelet agents were pre-
scribed to 93.3% and statins to 94.6% patients. Two patients
died during the hospital stay whereas the remaining 147 were
discharged in a stable condition after a median hospital stay
of 6 days (interquartile range 4e11 days).
does not provide absolute risk value once the estimated
10-year risk exceeds 30%. ACC, American College of
Cardiology; AHA, American Heart Association; FRS,
Framingham risk score; JBS, Joint British Society; WHO,
World Health Organization.4.2. Estimated 10-yr CV risk according to the different
risk scores (Table 3, Figs. 1e3)
The 10-year risk of major CV events (CVD death, MI or stroke)
was calculated in all patients using RiskFRS, RiskACC/AHA and
RiskWHO. However, RiskJBS could be applied only in 93 (62.4%)
patients as the body-mass index was not available in the
remaining patients (the patients could not be weighed
because of their clinical condition).
As shown in Table 3 and Figs. 1 and 2, RiskWHO provided the
lowest risk estimates with 61.7% patients estimated to be
having <10% risk and another 24.8% having 10e19.9% risk. In
comparison, RiskFRS and RiskACC/AHA returned higher risk es-
timates (61.7% and 69.8% identified to be having <20% risk,
respectively). However, RiskJBS identified the largest propor-
tion of the patients as being at ‘high-risk’ (55.9% with 20%
risk). All the p values were <0.01 for comparisons between any
two combinations of risk models but when the risk categoriesTable 3 e Estimated cardiovascular risk according to















charts (n ¼ 149)
<10% 34 (22.8) 18 (19.4) 57 (38.3) 92 (61.7)
10e19.9% 58 (38.9) 23 (24.7) 47 (31.5) 37 (24.8)
20e29.9% 20 (13.4) 19 (20.4) 23 (15.4) 10 (6.7)
30e39.9% 37 (24.8) 16 (17.2) 8 (5.4) 7 (4.7)
40% 17 (18.3) 14 (9.4) 3 (2.0)
p value <0.01 for all comparisons between any two combinations of
risk models. However, when the risk categories were dichotomized
(<20% and 20%), the difference between FRS and ACC/AHA risk
score was no longer significant (p value 0.10).
ACC, American College of Cardiology; AHA, American Heart Asso-
ciation; CV, cardiovascular; FRS, Framingham risk score; JBS, Joint
British Society; WHO, World Health Organization.
Fig. 2 e The estimated 10-year cardiovascular risk divided
into two risk categories as <20% and ≥20%. ACC, American
College of Cardiology; AHA, American Heart Association;
FRS, Framingham risk score; JBS, Joint British Society;
WHO, World Health Organization.
Fig. 3 e The correlation between the 10-year risk estimates
derived using the JBS risk score and the ACC/AHA risk
score. ACC, American College of Cardiology; AHA,
American Heart Association; JBS, Joint British Society.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 5 8 0e5 8 6584were dichotomized (<20% and >20%), the difference between
RiskFRS and RiskACC/AHA was no longer significant (p value
0.10). No significant correlation was found between RiskJBS
and RiskACC/AHA (Pearson's r 0.14, p value 0.17), the two most
recently developed risk scoring models.5. Discussion
To the best of our knowledge, this is the first study to have
compared the 4 clinically most relevant and contemporary CV
risk assessment models in Indian subjects. We found that in
patients presenting with first MI, RiskJBS was the most likely
and RiskWHO the least likely to recognize them as being at
‘high-risk’ of having CV events. The other two risk assessment
models (RiskFRS and RiskACC/AHA) had intermediate but com-
parable accuracy for this purpose.
5.1. The concept of CV risk assessment and the available
risk assessment models
Estimation of the risk of future CV events is a fundamental
concept in preventive cardiology. The ability to predict the
likelihood of future development of CV disease in a given in-
dividual allows matching the intensity of the risk-reduction
therapy with the anticipate risk and thereby facilitates judi-
cious and effective implementation of the preventive strategy.
The use of aspirin and/or statins for primary prevention of
atherosclerotic CVD represents the best example of a risk-
based therapeutic approach. In addition, the knowledge of
the anticipated future risk of adverse events also helps improve
patient compliance towards the preventive measures.
Traditionally, the assessment of the CV risk is performed
by determining the presence and severity of the major CV risk
factors and subsequently using risk algorithms and predictioncharts to determine the overall CV risk in any given individual.
A number of risk assessment tools are available for this pur-
pose, of which FRS1,2 remains the most widely used one. The
FRS is based on the data derived from the Framingham Heart
Study which was initiated in 1948 in the town of Framingham
in Massachusetts, USA. The initial FRS, which was developed
in 1998, predicted only coronary heart disease risk but sub-
sequently, a new general risk prediction tool was developed in
2008 to predict the overall CVD risk.1,2
While FRS has been validated in a number of populations
and has been the cornerstone of CV risk assessment over the
years, it has several limitations.21 First, it was developed at a
time when the CVD incidence was at its peak in the US. As a
result, FRS tends to overestimate CV risk in populations in
which the CVD incidence is much lower, such as in the Euro-
peans. Second, FRS does not take in to account many of
the non-conventional risk factors such as obesity, physical
inactivity, family history of premature CVD, etc which are
being increasingly recognized as important contributors to the
development of atherosclerotic CVD. Finally, FRS relies heavily
on age as a determinant of the CV risk. Consequently, in a
young individual, the estimated 10-year CV risk according to
FRS is invariably low, despite the presence of multiple CV risk
factors. This has important implications for Indians in whom
CVD tends to occur at a younger age than the western pop-
ulations. As a result, FRS is likely to underestimate CV risk in
Indians, as has been demonstrated in previous studies.15,22,23
To overcome some of these challenges, numerous other
risk assessment models have been developed for use in
different ethnic groups. In 2007, the WHO, in collaboration
with the International Society for Hypertension, published a
series of risk prediction charts, each dedicated to a different
ethnic-geographic region.8 These risk assessment charts were
derived with the help of statistical models using extrapolated
data about the prevalence of various CV risk factors in
different geographical regions. Although these risk prediction
charts have not been systematically validated in prospective
studies, they seem to be the only option available for the
populations for which prospective studies are not available.
More recently, two new risk scoring systems have become
available. The ACC/AHA task force on practice guidelines in
2013 developed a new risk assessment approach (RiskACC/AHA)
using pooled data from multiple cohorts, including the Fra-
mingham original and off-springs cohorts.9 The primary
objective for developing RiskACC/AHA was to guide cholesterol
management among adults and the task force recommends
that this new risk score be used instead of RiskFRS for all
decision-making regarding the use of statins in adults.24
However, the accuracy of RiskACC/AHA, even in American pop-
ulations, has become a matter of considerable debate.25,26 In
the mean almost at the same time, the 3rd iteration of the JBS
also came out with its own risk assessment model (RiskJBS).
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This risk score is applicable to the populations in the UK but
unlike most other risk scores, also provides risk estimates for
non-resident Indians.
5.2. CV risk assessment in Indians
It is well established now that South Asians, including In-
dians, have increased risk of CVD as compared to other
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 5 8 0e5 8 6 585populations.11e17 Both the genetic make-up and early onset of
conventional CV risk factors are believed to contribute to this
excess risk.12,13,17 Consistent with this, numerous studies
have shown that the risk assessment models developed for
western populations systematically underestimate risk in in-
dividuals of South Asian origin.11,14,15
The assessment of CV risk among resident Indians is even
more challenging. No prospective data is available for Indians
to facilitate risk assessment in them and as a result the Indian
physicians have to follow the same risk assessment models
that are being used for western populations. Unfortunately,
very little information is available to demonstrate how well
these various risk scoring systems perform among resident
Indians. In a previous study involving executives with meta-
bolic syndrome, we found that RiskFRS could identify only
23.3% as having intermediate to high-risk.22 Similar findings
were reported by Kanjilal et al also.23 They compared 3
different risk scoring systems e RiskFRS, SCORE and an older
version of JBS risk score in the family members of the patients
with CVD. It was found that despite significantly elevated
levels of lipids, pro-inflammatory, pro-thrombotic, and sero-
logical markers, all 3 risk scores identified <5% population as
being at ‘high-risk’.
Various alternate approaches have been proposed to
facilitate CV risk assessment among Indians. Some in-
vestigators have suggested recalibrating the FRS by multi-
plying the calculated FRS by an appropriate correction
factor.27 Alternately, RiskWHO offers a specific chart for resi-
dent Indians that could potentially be more accurate for our
population. Yet another option is to use RiskJBS that includes
data on ethnic Indians, albeit non-resident. In this context,
the findings of our study assume significance. We found that
in patients presenting with acute MI, RiskJBS provided the
highest risk estimates among all the risk assessment models
compared. The difference was even more marked given the
fact that in some individuals we had to use higher than actual
values of SBP and TC to meet the lower limits accepted by
RiskACC/AHA and RiskWHO. There could be several explanations
why RiskJBS was found to be more accurate in our study. First,
RiskJBS is the only risk assessment model that has been vali-
dated in ethnic Indians, even though non-resident ones. Sec-
ond, RiskJBS is a more comprehensive risk assessment model
and takes in to account several additional risk factors such as
obesity and family history of premature CVD. Inclusion of
these risk factors is likely to enhance the accuracy of risk
prediction. Third, as mentioned above, the accuracy of Ris-
kACC/AHA is already a subject of controversy and is likely to be
questionable in Indians also for whom it was actually never
designed. However, it is difficult to explain why RiskWHO
seemed to most underestimate the risk in our study.
5.3. Presentation with acute MI as the clinical setting in
the present study
It must be noted that all the available CV risk assessment
models have been designed only for predicting future risk of
CV events and not for use in a cross-sectional manner as has
been done in the present study (and some of the previous
ones).22,23,28 However, in the absence of long-term prospec-
tive studies, this remains the only approach available toevaluate the predictive accuracy of different risk assessment
algorithms. Compared to the previous similar studies, our
study indeed had some strong points. We included only
those patients who had presented with acute MI. Thus, there
was no ambiguity that the patients included in our study
were actually at a significantly high risk of having a major
CV event. In contrast, in the study by Kanjilal et al, relatively
lower risk asymptomatic subjects were included and as no
follow up information was available, it was impossible to
confirm the true CV risk in them.23 In addition, unlike the
previous studies, we did not selectively include only the
young subjects.22,23,28 It is well known that in young sub-
jects, most risk assessment algorithms seem to underesti-
mate the 10-year risk.6. Limitations
There are several limitations of our study that warrant
attention. First, some of our patients were already on statins,
which must have lowered their cholesterol values. These
values must have been lowered even further by the occur-
rence of the acute coronary event, though the impact of an
acute coronary event on cholesterol levels is relatively less
marked during the initial 24 h of symptoms onset. In the same
manner, it is also likely that the SBP at the time of presenta-
tion may have been lower than the actual level. These alter-
ations are expected to have resulted in underestimation of CV
risk in our study. However, as both TC and SBP are included in
all the four risk assessment models compared in the present
study, it is unlikely that any changes in TC or SBP would
differentially affect one risk score more than the other.
Therefore, as the primary objective of the present studywas to
compare different risk assessment models and not to derive
absolute risk estimates, we believe our study findings were
not significantly affected by these factors.
Second, as already discussed above, the only appropriate
method to assess the predictive accuracy of different risk
assessment methods is to perform a long-term prospective
study. However, the rationale behind our approach and the
potential strength of our study over the previous similar ones
have also been discussed above. In fact, as no prospective
study seems to be currently underway to address this issue,
our findings provide valuable information that is likely to have
significant clinical implications.
Finally, our study had relatively small sample size. How-
ever, as we included only the patients presenting with acute
MI, we were able to collect reasonable number of hard CV
events to derive meaningful conclusions from it.7. Conclusions
This is the first study to show that in Indian patients pre-
senting with acute MI, RiskJBS is likely to identify the largest
proportion of the patients as at ‘high-risk’. RiskWHO un-
derestimates the risk the most whereas RiskFRS and RiskACC/
AHA have intermediate accuracy. These findings suggest that
RiskJBS may be more suited for use in Indians. However, large-
scale prospective studies are needed to confirm these findings.
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